Erlotinib Hydrochloride CAS 183319-69-9 Purity >99.0% (HPLC)

Short Description:

Chemical Name: Erlotinib Hydrochloride

Synonyms: Erlotinib HCl; Tarceva

CAS: 183319-69-9

Purity (HPLC): >99.0%

Appearance: White to Off-White Crystalline Powder

Contact: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Leading manufacturer and supplier of Erlotinib Hydrochloride Intermediates

Erlotinib Hydrochloride	CAS 183319-69-9
3-Ethynylaniline	CAS 54060-30-9
6,7-Bis(2-Methoxyethoxy)-4(3H)-Quinazolinone	CAS 179688-29-0

Please contact: alvin@ruifuchem.com

Chemical Properties:

Chemical Name	Erlotinib Hydrochloride
Synonyms	Erlotinib HCl; Tarceva; CP-358774 Hydrochloride; 6,7-Bis(2-methoxyethoxy)-4-(3-ethynylanilino)quinazoline Hydrochloride; N-(3-Ethynylphe nyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine HCl
CAS Number	183319-69-9
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C22H24ClN3O4
Molecular Weight	429.90
Melting Point	223.0~229.0℃
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White to Off-White Crystalline Powder
Identification	A: IR: Conresponding to Reference Spectrum B: HPLC: Conresponding to Reference RT
Solubility	Very Slightly Soluble in Water, Slightly Soluble in Methanol and Practically Insoluble in Acetonitrile, Acetone, Ethyl Acetate and Hexane
Melting Point	223.0~229.0℃
Loss on Drying	<0.50%
Residue on Ignition	<0.20%
Heavy Metals	<20ppm
Single Impurity	<0.50%
Total Impurities	<1.00%
Residual Solvents
Pyridine	<4000ppm
Chloroform	<4000ppm
DMF	<3000ppm
Purity / Analysis Method	>99.0%
Assay / Analysis Method	98.5%~101.0% (Caculated on Anhydrous Basis)
Test Standard	Enterprise Standard
Usage	API

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

183319-69-9 - Application:

Erlotinib Hydrochloride (CAS: 183319-69-9) is a small molecule of epidermal growth factor receptor tyrosine kinase reversible inhibitor, is mainly used in the treatment of locally advanced or metastatic non small cell lung cancer and second-line or three line treatment of pancreatic cancer. Erlotinib Hydrochloride was approved in November, 2004, for the treatment of advanced or metastatic non-smallcell lung cancer. It belongs to the same class as Gefitinib, another quinazoline approved for treatment of advanced lung cancer, but with improved pharmacokinetic properties. The molecule was originated by Pfizer and development initiated in collaboration with OSI, which assumed full rights to the drug when Pfizer merged with Warner Lambert. Subsequently, Genentech/Roche went into licensing agreement with OSI to develop and market the drug in the US and Worldwide. Selective epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor. Antineoplastic. Erlotinib Hydrochloride is an HER1/EGFR inhibitor with IC50 of 2 nM. Erlotinib HCl is available as 25-, 100-, and 150-mg tablets fororal administration.

183319-69-9 - Mechanism of Action:

Erlotinib Hydrochloride (CAS: 183319-69-9) targets epidermal growth factor receptor subtype (EGFR-TK) that reversibly and selectively acts on tyrosine kinase receptors. Its mechanism of action is to compete with substrates in cells, inhibit EGFR-TK phosphorylation, block tumor cell signal transduction, inhibit tumor cell growth, and induce apoptosis. Clinical studies have shown that the drug has an inhibitory effect on a variety of tumors. Compared with traditional chemotherapy drugs, it has the advantages of lighter adverse reactions, better safety and tolerance.

183319-69-9 - Biological Activity:

Erlotinib Hydrochloride (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor. in cell-free tests, the IC50 is 2 nM, and the selectivity for EGFR is more than 1000 times higher than that for human c-Src or v-Abl.